Clinical application of volumetric absorptive microsampling to the gefapixant development program
other
OA: closed
public-domain-us
AI-generated summary
This paper details the development and validation of a liquid chromatography-tandem mass spectrometry bioanalytical method using volumetric absorptive microsampling (VAMS) to support the gefapixant drug development program.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
In this paper we show the application of the Tasso OnDemand™, a novel automated sample collection device, in conjunction with volumetric absorptive microsampling (VAMS) for the development of gefapixant, a P2X3 receptor antagonist currently under clinical development for the treatment of refractory and unexplained chronic cough and endometriosis-related pain. A LC-MS/MS bioanalytical method was developed and validated using VAMS to support this development program. This method was utilized in a drug-drug interaction study to establish a mathematical bridging relationship with data obtained from a validated plasma assay used to support the program. The VAMS bioanalytical method and the predictability of the mathematical relationship is reported and discussed here.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-08-09T06:10:49.860119+00:00
- pubmed
- last seen: 2026-05-13T22:21:53.586419+00:00
- unpaywall
- last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine